Access without published appraisal: orphan medicine reimbursement and health equity in Türkiye
Abstract Rare diseases are individually uncommon but collectively affect a substantial share of any population. The medicines developed for them combine severe conditions, very small treatable populations, high prices, and evidence that is often immature at launch. Conventional cost-effectiveness analysis handles this...